Consciousness · Pillar

Psilocybin — legal status, research, and policy.

Psilocybin is the most studied psychedelic compound in modern clinical psychiatry, and at the same time one of the most legally complicated substances in the United States. The science is moving faster than the law, and the law is moving differently in every jurisdiction. This hub tracks where the research, the policy, and the public conversation actually stand.

The legal landscape

Where psilocybin stands in the United States right now.

Federal law classifies psilocybin as a Schedule I controlled substance. State and city laws diverge significantly.

Jurisdiction	Status	Notes
Oregon	Legal (regulated)	The Oregon Psilocybin Services Program (Measure 109) — supervised therapeutic sessions in licensed service centers.
Colorado	Legal (regulated, phased)	Proposition 122 created a regulated framework; first service centers open 2025–2026.
Denver, CO	Decriminalized (2019)	Personal possession deprioritized for prosecution.
Oakland, CA	Decriminalized (2019)	Plant-medicine resolution.
Santa Cruz, CA	Decriminalized (2020)
Washington, D.C.	Decriminalized (2020)	Initiative 81 — personal use deprioritized.
Seattle, WA	Decriminalized (2021)
Detroit, MI	Decriminalized (2021)
Massachusetts cities	Decriminalized (2021–2023)	Somerville, Cambridge, Northampton, Easthampton, Salem, Provincetown.
San Francisco, CA	Decriminalized (2022)
All other states	Illegal (federal Schedule I applies)	Possession remains a state-level felony or misdemeanor depending on jurisdiction.

Decriminalized ≠ legal. Decriminalization means law enforcement deprioritizes prosecution of personal possession. It does not legalize sale, cultivation, or distribution — and local prosecution discretion still exists. Read the complete state-by-state guide →

The evidence

What the clinical research actually shows.

Psilocybin is currently in Phase III FDA trials for treatment-resistant depression under breakthrough therapy designation. Earlier work at Johns Hopkins, Imperial College London, NYU, and Yale has produced effect sizes that are unusual in psychiatric research.

Treatment-resistant depression

Multiple Phase II trials show 50–70% remission rates from a single or two-session protocol, with effects persisting at 6- and 12-month follow-up in published studies.

End-of-life anxiety

Landmark NYU and Johns Hopkins trials (2016) showed sustained reductions in anxiety and depression in cancer patients facing terminal diagnoses.

Smoking cessation

Hopkins pilot work suggests psilocybin-assisted therapy may outperform existing pharmacological cessation treatments; replication studies are in progress.

Alcohol use disorder

Phase II results published in 2022 show meaningful reductions in heavy drinking days post-treatment.

Cluster headaches

Emerging clinical and case-series evidence for prophylactic effects, currently in formal trials.

What the research does not yet show

Long-term safety data beyond 12-month follow-up (trials are ongoing).
Equivalent efficacy for major depression in non-treatment-resistant populations.
Effects in adolescents — no clinical trials in under-18 populations to date.
Safety in combination with common psychiatric medications (interaction studies are limited).
Cost-effectiveness vs existing therapies at scale (modeling in progress).

Regulated programs

Oregon and Colorado, explained.

These are the two U.S. jurisdictions with active legal frameworks for supervised psilocybin services. They differ in important ways.

Oregon — Measure 109 (operational 2023)

Legal for adults 21+ to access services at licensed centers under a licensed facilitator.
Not a medical model — Oregon explicitly chose not to require a diagnosis or prescription.
Services include preparation, a supervised dosing session (typically 6 hours), and integration.
Roughly $1,000–$3,000 per full program, paid out of pocket; insurance does not cover it.
Service centers concentrated in Portland and Eugene; rural coverage is limited.

Colorado — Proposition 122 (phased 2025–2026)

Broader scope than Oregon — includes psilocybin and psilocyn, with DMT, ibogaine, and mescaline in later phases.
Personal-use possession also decriminalized for adults 21+.
Service-center model similar to Oregon, with first centers opening as of 2026.
Healing centers operate within a state framework, with more flexible facilitator credentialing.

Harm reduction context

Why we cover it, and how.

We cover harm reduction because it is part of comprehensive public health information. We do not endorse, encourage, or provide instruction for personal use outside of legal regulated contexts. The general principles published by organizations like the Drug Policy Alliance and MAPS:

Set and setting matter — environment, mindset, and trip-sitter presence are the strongest predictors of a difficult vs supportive experience.
Drug interactions are real — SSRIs, MAOIs, lithium, and tramadol all have documented or theoretical interactions; psychotic-spectrum illness is a strong contraindication.
Dose escalation is irreversible mid-session.
Integration matters — what happens afterward determines whether the experience produces durable change.

Resources: Drug Policy Alliance, MAPS, Erowid.

Policy tracking

What's in motion.

Federal scheduling, state legislation, and city decriminalization are all shifting. We track:

The FDA approval timeline for psilocybin-assisted therapy.
State legislative bills under consideration (WA, MA, NY, NJ, CA, NM, IL).
Federal moves — DEA scheduling petitions, Congressional research authorizations.
International developments — Australia approved psilocybin for TRD in 2023; the Netherlands' truffle market continues; Canadian Special Access Programs.

The boundary

What we will not publish.

Mycology Minded does not, and will not, publish:

Cultivation guides for psilocybin-containing species.
Sourcing information for spores, mycelium, or fruiting bodies of psilocybin species.
Dose calculators or trip planners.
"How-to" guides for personal use, even in decriminalized jurisdictions.
Anything that could reasonably be interpreted as facilitating a Schedule I offense.

This is a journalistic boundary, not a moral one. We cover the field; we do not facilitate it.